

IMMUNOGEN INC
Form 8-K
July 31, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **JULY 31, 2003**

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction
of incorporation)

0-17999
(Commission
File Number)

04-2726691
(IRS Employer
Identification No.)

128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: **(617) 995-2500**

ITEM 5. OTHER EVENTS

On July 31, 2003, ImmunoGen, Inc. announced that the Company signed a collaboration agreement with Aventis to discover, develop and commercialize novel anticancer therapeutics. The press release announcing this event is incorporated herein by reference and filed as Exhibit 99.1 hereto.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c)
Exhibits

Exhibit

Exhibit
No.

99.1 The Registrant's Press Release dated July 31, 2003.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc.
(Registrant)

Date: JULY 31, 2003

/s/ GREGG D. BELOFF

Gregg D. Beloff
Chief Financial Officer and
Vice President, Finance

3

EXHIBIT INDEX

Exhibit
No. Exhibit

99.1 The Registrant's Press Release dated July 31, 2003.

QuickLinks

[ITEM 5. OTHER EVENTS](#)

[ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)